Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunization Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia

NCT06505993
View directory record Official record
Conditions
COVID-19, Vaccine Hesitancy
Interventions
Health Communication, Health Communication + Structural
Behavioral
Lead sponsor
Marc Kiviniemi
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 12:06 AM EDT
Recruiting Phase 1 Interventional

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852
View directory record Official record
Conditions
Hepatitis B, Chronic Hepatitis B
Interventions
Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Melanoma

NCT00020358
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, incomplete Freund's adjuvant, tyrosinase peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 21, 2026, 12:06 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

NCT00001064
View directory record Official record
Conditions
HIV Infections
Interventions
Allogenic Dendritic Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

NCT01823536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
7 Years to 15 Years
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
15
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 21, 2026, 12:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
View directory record Official record
Conditions
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

NCT01765426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Galveston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 21, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo

NCT00001540
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 21, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters

NCT00937287
View directory record Official record
Conditions
Human Papillomavirus
Interventions
There is no intervention in this study.
Other
Lead sponsor
University of Georgia
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Not applicable Interventional Results available

Presumptively Initiating Vaccines and Optimizing Talk With Motivational Interviewing (PIVOT With MI)

NCT03885232
View directory record Official record
Conditions
Preventive Health Services (PREV HEALTH SERV)
Interventions
Experimental: PIVOT with MI, Active Comparator: Control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Months
Enrollment
17,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 1 Interventional

Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma

NCT00061035
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Transgenic Lymphocyte Immunization Vaccine (TLI)
Biological
Lead sponsor
Cosmo Bioscience
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2008 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 vaccine, Control
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
3,855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 1 Interventional

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

NCT00393276
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Twinrix, Decavac
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaccine Hesitancy Intervention--Provider (VHIP)

NCT01667354
View directory record Official record
Conditions
Childhood Vaccination
Interventions
Academic Detailing
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
491 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 21, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination

NCT03209713
View directory record Official record
Conditions
Parents
Interventions
HPV Vaccine Education, Text Messaging Reminder
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 84 Years
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Las Vegas, Nevada • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 12:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The STOP-HPV Trial 4: Bundle Intervention

NCT03609242
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
STOP-HPV bundle intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 21, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strengthening Intentions

NCT07222774
View directory record Official record
Conditions
Influenza Vaccination, Behavior And Behavior Mechanism
Interventions
Experimental
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 21, 2026, 12:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Facilitating Completion of HPV Vaccination

NCT01600560
View directory record Official record
Conditions
Adolescent Immunizations Among Clinic Population
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 21 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 1 Interventional

Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

NCT00458679
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis B Vaccine in Seniors

NCT04162223
View directory record Official record
Conditions
Hepatitis B Vaccination
Interventions
Subcutaneous fat injection of Recombivax-HB, Intramuscular injection of Recombivax-HB
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1

NCT06650462
View directory record Official record
Conditions
COVID-19, Trust
Interventions
Community-led discussion
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ETEC Logistics Trial (TREK)

NCT00516659
View directory record Official record
Conditions
Diarrhea
Interventions
Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
13
States / cities
Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 21, 2026, 12:06 AM EDT